The Nasdaq-to-OTCQB transition is a material negative catalyst that will reduce liquidity and institutional interest. Monitor for FDA feedback in mid-2026 as the only near-term binary event. The $22.2M cash position provides runway into late 2026, but the OTCQB listing makes follow-on financing more dilutive.
Price Chart
Executive Summary
Reviva Pharmaceuticals reported Q1 2026 net loss of $3.2M ($0.46/share), narrower than the year-ago $6.4M loss ($2.61/share), but the EPS of -$0.46 missed the consensus estimate of -$0.29 by 58.6%. The company is advancing its brilaroxazine program with FDA feedback expected mid-2026 and RECOVER-2 Phase 3 enrollment in Q3 2026, but its stock is transitioning from Nasdaq to OTCQB effective May 14, 2026, which severely limits liquidity and access to capital.
Key Financial Metrics
Key Facts
- Q1 2026 net loss of $3.2M ($0.46/share) vs $6.4M ($2.61/share) in Q1 2025
- EPS of -$0.46 missed consensus estimate of -$0.29 by 58.6%
- Cash and equivalents $22.2M as of March 31, 2026, up from $14.4M at year-end 2025
- Common stock transitioning from Nasdaq to OTCQB effective May 14, 2026
- Completed $10M public equity offering in March 2026
- FDA feedback on new brilaroxazine form expected mid-2026; RECOVER-2 Phase 3 enrollment expected Q3 2026
Financial Impact
EPS miss of 58.6% vs consensus; net loss improved YoY but still significant burn rate of ~$3.2M/quarter
Risk Factors
- OTCQB listing severely limits liquidity and institutional ownership
- Cash burn of ~$3.2M/quarter with no revenue; may require dilutive financing
- FDA feedback on brilaroxazine form is binary and could delay RECOVER-2 trial
- Historical performance shows high volatility with negative average T+20 returns (-11.93%)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294478 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 7w ago | Press Release | $0.3521 $0.3521 | · 0.00% | ▲ +1.75% | $0.5000 (+42.01%) |
Jul 10, 2026 12w ago | 25-NSE | $0.6200 $0.4775 | ▲ +22.98% | ▲ +25.40% | $0.5000 (+19.35%) |
May 13, 2026 20w ago | Press Release | $0.3900 $0.6839 | ▼ −75.36% | ▼ −76.22% | $0.5000 (−28.21%) |
May 13, 2026 20w ago | 8-K | $0.3521 $0.7600 | ▼ −115.85% | ▼ −116.46% | $0.5000 (−42.01%) |
Apr 15, 2026 24w ago | 8-K | $0.8900 $0.8000 | ▼ −10.11% | ▼ −16.16% | $0.5000 (−43.82%) |
Mar 30, 2026 26w ago | Press Release | $0.6600 $0.8800 | ▲ +33.33% | ▲ +20.74% | $0.5000 (−24.24%) |
Mar 19, 2026 28w ago | Press Release | $0.8300 $0.8500 | ▼ −2.41% | ▲ +5.21% | $0.5000 (+39.76%) |
Mar 18, 2026 28w ago | Press Release | $0.8300 $0.8500 | ▲ +2.41% | ▼ −5.21% | $0.5000 (−39.76%) |
Mar 5, 2026 30w ago | 8-K | $4.20 $0.7200 | ▼ −82.86% | ▼ −79.07% | $0.5000 (−88.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access